Zanubrutinib (tablet) for treating Waldenström’s macroglobulinaemia, marginal zone lymphoma, chronic lymphocytic leukaemia, mantle cell lymphoma, or refractory or relapsed follicular lymphoma

Zanubrutinib tablets are in clinical development as a bioequivalent to zanubrutinib capsules. To treat adult patients with Waldenström’s macroglobulinaemia (WM) or refractory (unresponsive to treatment) or relapsed (returned following remission) marginal zone lymphoma (MZL) or chronic lymphocytic leukaemia (CLL) or refractory or relapsed mantle cell lymphoma (MCL) or in combination with obinutuzumab for refractory or relapsed follicular lymphoma (FL). WM, MZL, CLL, MCL and FL are types of cancer, which develop over time in the lymphatic system, which is part of the immune system.